FINWIRES · TerminalLIVE
FINWIRES

German Flash Annual Inflation Rises to 2.9% in April

作者

-- Germany's annual inflation rate rose to 2.9% in April from 2.7% in March, according to provisional data from the country's Federal Statistical Office published Wednesday.

The latest reading is below the consensus estimate of 3%.

On a monthly basis, consumer prices were 0.6% higher, against the previous 1.1% increase and the expected 0.7% rise.

The annual harmonized inflation rate was 2.9%, compared with the prior 2.8% and the market forecast of 3.1%. Meanwhile, harmonized consumer prices were up 0.5% month over month, against the previous reading of a 1.2% gain and the expected 0.8% rise.

相關文章

Australia

Ryde與VinaTaxi簽署諒解備忘錄,探索越南市場機會

Ryde集團(RYDE)週三宣布,已與VinaTaxi簽署諒解備忘錄,共同探索在越南的戰略合作機會。 該公司表示,合作探索的領域包括在VinaTaxi的計程車車隊中部署Ryde的平台,以及開發電動摩托車出行生態系統。Price: $1.20, Change: $+0.02, Percent Change: +1.61%

$RYDE
Australia

Emergent BioSolutions 簽署價值 5000 萬美元的合同,為 SAB Biotherapeutics 的領先項目提供支持

Emergent BioSolutions (EBS) 週三宣布,已與 SAB Biotherapeutics (SABS) 簽署一項價值 5000 萬美元的多年期協議,以推進 SAB-142 的臨床開發,該藥物用於治療自身免疫性 1 型糖尿病。 根據協議,其中 3,600 萬美元的款項取決於未來的監管審批和後續里程碑的達成情況。 Emergent BioSolutions 表示,將提供符合現行良好生產規範 (cGMP) 的端到端開發和生產服務。Price: $8.17, Change: $-0.07, Percent Change: -0.79%

$EBS$SABS
Australia

Immunome公司提交了基於3期臨床試驗數據的Varegacestat新藥申請。

Immunome(IMNM)週三宣布,已向美國食品藥物管理局(FDA)提交了新藥申請,申請上市的藥物為varegacestat,一種用於治療成人纖維瘤的在研口服藥物。 該公司表示,此次申請基於積極的3期RINGSIDE試驗結果,結果顯示與安慰劑相比,varegacestat顯著改善了患者的無進展生存期,降低了84%的疾病進展或死亡風險,客觀緩解率達到56%。 該公司補充說,試驗的詳細數據將在2026年美國臨床腫瘤學會(ASCO)年會上發表。 Immunome股價週三下跌2.7%。Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM